Skip Navigation

European Heart Journal 1994 15(Supplement C):82-88; doi:10.1093/eurheartj/15.suppl_C.82
Copyright © 1994 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Haeusler, G.
Right arrow Articles by Lues, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haeusler, G.
Right arrow Articles by Lues, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1994 The European Society of Cardiology

Therapeutic Potential of Potassium Channel Activators in Coronary Heart Disease

G. Haeusler and I. Lues

Department of Pharmaceutical Research and Development E. Merck, Frankfurter Strasse 250, D-6100 Darmstadt Germany

Correspondence: G. Haeusler, Department of Pharmaceutical Research and Development. E. Merck, Frankfurter Strasse 250. D-6100 Darmstad, Germany

Potassium channel activators have the ability to open potassium channels in a variety of cells Since most of their effects are antagonized by antidiabetic sulfonylureas, the ATP-sensitive potassium channel is their likely target. Opening of potassium channels leads to hyperpolarization of the surface membrane with consequent closure of voltage-dependent ion channels and reduction of free intracellular calcium ions. Currently available potassium channel activators, including aprikalim, bimakalim, cromakalim, emakalim, nicorandil, pinacidil etc., display a high affinity for potassium channels of vascular smooth muscle. Vasodilation and a reduction in systemic vascular resistance are their prominent pharmacological effects.

Coronary and cerebral arteries are highly sensitive to potassium channel activator-induced dilation. Apart from treatment of hypertension, potassium channel activators appear to have therapeutic potential in coronary heart disease. They reduce cardiac afterload, increase native and collateral coronary blood flow and reduce the size of experimental myocardial infarcts. This last effect cannot be satisfactorily explained entirely by haemodynamic or coronary vascular actions of potasium channel activators and a cardioprotective effect is postulated. For these drugs ischaemia-induced and activatorinduced opening of cardiac ATP-sensitive potassium channels appear to work in concert. Nicorandil combines the pharmacological properties of an organic nitrate with those of potassium channel activators. Experimenta1 and clinical results characterize nicorandil as a unique and promising drug for the treatment of coronary heart disease.

Key Words: ATP-sensitive potassium channels • cardioprotection • coronary heart disease • nicorandil • potassium channel activators


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.